ArticleJournal of managed care & specialty pharmacy2026
Real-time continuous glucose monitoring related to reductions in inpatient and emergency department encounters and their associated costs among non-insulin-treated people with type 2 diabetes.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of real-time continuous glucose monitoring (RT-CGM) is well established to support people with type 2 diabetes (T2D) in achieving adequate glycemic control. However, health care resource utilization (HCRU) studies have previously tended to focus on individuals with T2D who are receiving treatment with insulin.
objectiveTo examine the impacts of RT-CGM on inpatient and emergency department (ED) HCRU in non-insulin-treated people.
methodsThis retrospective study analyzed US administrative claims data from Optum's Clinformatics Data Mart database between September 1, 2016, and December 31, 2024. Continuous glucose monitoring (CGM)-naive individuals with T2D who initiated a Dexcom G-series RT-CGM between September 1, 2017, and December 31, 2023, were included (index date: first RT-CGM claim). Change in the number of all-cause and diabetes-related encounters by service location (inpatient and ED) and the mean change in associated medical costs were assessed over a 6-month pre-index period (baseline) and in 2 consecutive 6-month segments post-index (0-6 months and 7-12 months). Stratification by baseline HCRU encounter frequency unique to service location included the following: nonutilizers, zero baseline encounters; low utilization, 1 to 2 baseline encounters; high utilization, 3 or more baseline encounters.
resultsThe analysis included 4,463 people with T2D. Decreases were observed in the numbers of inpatient and ED encounters among those using such encounters in the baseline period. Those considered that low utilizers (1-2 baseline encounters) experienced a 66% decrease in inpatient encounters and 63% decrease in ED encounters, whereas high utilizers (≥3 encounters) experienced a 67% decrease in inpatient encounters and 68% decrease in ED encounters. These decreases coincided with significant reductions in associated costs.
conclusionsPeople with T2D who were not receiving insulin treatment and have had recent inpatient or ED encounters had lower observed HCRU after the initiation of RT-CGM with Dexcom G-series systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.